Back to Medtronic

Medtronic News

MDT

MDT AGM: Directors, Auditor & Share Issuance

Medtronic (MDT) shareholders elected directors, approved the auditor and authorized share issuance at the 2026 AGM. Key governance and capital implications.

MDT

Medtronic Completes MiniMed Separation (MDT)

Medtronic (MDT) finalizes MiniMed Group, Inc. separation on 2026-10-19; relates to Diabetes unit, following Dec 2025 restructuring and $16M Q3 FY2026 charge.

MDT

Medtronic Names President for Greater China

Medtronic (MDT) appoints Michael Marinaro as President overseeing Greater China on Oct 19, 2026. Key investor implications for international revenue and strategy.

MDT

Medtronic Buyback Approved — MDT Repurchase

Medtronic shareholders approve overseas share repurchase, enabling part of the $5.0B buyback authorization; implications for capital allocation and leverage.

MDT

Medtronic Launches MiniMed Exchange Offer

Medtronic (MDT) begins MiniMed share exchange and corrects the offer's tender deadline as part of its planned Diabetes separation.

MDT

Medtronic Completes CathWorks & Anteris Deals

Medtronic (MDT) completes two cardiovascular acquisitions — CathWorks and Anteris — in Q3 FY26. Strategic move to expand Cardiovascular portfolio; key financial context included.

MDT

MDT: Medtronic Gains Key Regulatory Approvals

Medtronic (MDT) secures CE Mark and FDA clearances in Q3 FY26, a regulatory step supporting product launches across device portfolios.

MDT

Medtronic Issues $419M in New Shares — MDT

Medtronic (MDT) raised $419M via new share issuance in the nine months to Jan 23, 2026. Context on capital allocation, repurchase plans and balance-sheet risks.

MDT

Medtronic Q3 Report: Growth, Guidance Upheld

MDT Q3: strong revenue, FDA approvals, CathWorks M&A progress, MiniMed separation underway; company upholds full-year guidance.

MDT

Medtronic Reports Strategic Growth Shift (Q3 FY26)

MDT Q3 FY26: revenue rose 8.7% driven by Cardiovascular strength and acquisitions. MiniMed separation, CathWorks option, $5B buyback and legal/tax risks noted.

MDT

MDT: No New Divestitures; Legacy Impacts Persist

Medtronic (MDT) reports prior exits continue to affect results; no new divestitures announced. Segment revenue, MiniMed separation, legal and tax risks detailed.

MDT

MDT: No New Divestitures Reported This Quarter

Medtronic (MDT) 8-K: no new divestitures this quarter. 8-K outlines impacts from prior sales and relates to portfolio moves including MiniMed separation.

MDT

MDT Q3 FY26: Revenue Up 8.7%, EPS Mixed

Medtronic (MDT) Q3 FY26: revenue rose 8.7% while GAAP and non‑GAAP EPS diverged. Segment, geographic breakdown and risks for investors (Feb 17, 2026).

MDT

Medtronic Issues $419M in New Shares (MDT)

Medtronic (MDT) issued $419M in new shares in the nine months to Jan 2026. Summary, context and investor implications for capital allocation and risk.

MDT

MDT: EVP Gregory L. Smith to Retire in Dec 2025

Medtronic (MDT) EVP Gregory L. Smith will retire in Dec 2025; company to accelerate vesting of outstanding equity awards. Investor implications and context.

MDT

Medtronic Re-elects 12 Board Directors (MDT)

Medtronic (MDT) re-elected 12 directors at its 2025 AGM. Board continuity preserves oversight of MiniMed separation, M&A, capital allocation and risks.

MDT

Medtronic Updates Shareholder Rights - MDT

Medtronic amends its Articles to revise voting and share issuance rules. Key implications for governance, dilution risk and capital allocation for investors.

MDT

Medtronic Refinances Senior Notes, Issues €1.5B

Medtronic (MDT) repays €500M notes and issues €1.5B in new senior debt as part of its debt-management and capital allocation strategy.

MDT

Medtronic Issues €1.5B Senior Notes

Medtronic (MDT) issues €1.5B in senior notes on Sept 16, 2025 and uses proceeds to redeem €500M of outstanding debt; impact on capital structure and investor risks.